SHMT1 1420 and MTHFR 677 variants are associated with rectal but not colon cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Komlósi, Viktor ^a   Hitre, Erika ^b   Pap, Éva ^b   Adleff, Vilmos ^b   Réti, Andrea ^b   Székely, Éva ^c   Bíró, Anna ^d   Rudnai, Péter ^e   Schoket, Bernadette ^e   Müller, Judit ^a   Tóth, Béla ^a   Ottó, Szabolcs ^b   Kásler, Miklós ^b   Kralovánszky, Judit ^b   Budai, Barna ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c Szent Laszlo Hospital   (Hungary)

^d National Institute of Chemical Safety   (Hungary)

^e NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYSTEINE; GLYCINE HYDROXYMETHYLTRANSFERASE; HOMOCYSTEINE; SERINE HYDROXYMETHYLTRANSFERASE 1; THREONINE; TUMOR MARKER; UNCLASSIFIED DRUG; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); SHMT1 PROTEIN, HUMAN;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER RISK; CANCER STAGING; COLON CANCER; CONTROLLED STUDY; FEMALE; FOLATE METABOLISM; GENE DOSAGE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; RECTUM CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; WILD TYPE; AGED; CASE CONTROL STUDY; COLON TUMOR; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; RECTUM TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GLYCINE HYDROXYMETHYLTRANSFERASE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECTAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77957286796     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-525     Document Type: Article

References (56)

1. Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J Nutr 2002, 132:2350S-2355S.
2. van Guelpen B, Hultdin J, Johansson I, Hallmans G, Stenling R, Riboli E, Winkvist A, Palmqvist R. Low folate levels may protect against colorectal cancer. Gut 2006, 55:1461-1466. 10.1136/gut.2005.085480, 1856405, 16638790.
3. Sharp L, Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 2004, 159:423-443. 10.1093/aje/kwh066, 14977639.
4. Ulvik A, Vollset SE, Hansen S, Gislefoss R, Jellum E, Ueland PM. Colorectal cancer and the methylenetetrahydrofolate reductase 677C- > T and methionine synthase 2756A- > G polymorphisms: a study of 2,168 case-control pairs from the JANUS cohort. Cancer Epidemiol Biomarkers Prev 2004, 13:2175-2180.
5. Chen K, Jiang QT, He HQ. Relationship between metabolic enzyme polymorphisms and colorectal cancer. World J Gastroenterol 2005, 11:331-335.
6. Hubner RA, Houlston RS. MTHFR C677T and colorectal cancer risk: a meta-analysis of 25 populations. Int J Cancer 2006, 120:1027-1035.
7. Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR, Rollinson S, Roman E, Cartwright RA, Morgan GJ. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 2002, 99:3786-3791. 10.1182/blood.V99.10.3786, 11986237.
8. Hishida A, Matsuo K, Hamajima N, Ito H, Ogura M, Kagami Y, Taji H, Morishima Y, Emi N, Tajima K. Associations between polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and susceptibility to malignant lymphoma. Haematologica 2003, 88:159-166.
9. van den Donk M, Visker MH, Harryvan JL, Kok FJ, Kampman E. Dietary intake of B-vitamins, polymorphisms in thymidylate synthase and serine hydroxymethyltransferase 1, and colorectal adenoma risk: a Dutch case-control study. Cancer Lett 2007, 250:146-153. 10.1016/j.canlet.2006.10.002, 17113224.
10. Chen J, Kyte C, Valcin M, Chan W, Wetmur JG, Selhub J, Hunter DJ, Ma J. Polymorphisms in the one-carbon metabolic pathway, plasma folate levels and colorectal cancer in a prospective study. Int J Cancer 2004, 110:617-620. 10.1002/ijc.20148, 15122597.
11. Guerreiro CS, Cravo M, Costa AR, Miranda A, Tavares L, Moura-Santos P, MarquesVidal P, Nobre Leitão C. Risk of colorectal cancer associated with the C677T polymorphism in 5,10-methylenetetrahydrofolate reductase in Portuguese patients depends on the intake of methyl-donor nutrients. Am J Clin Nutr 2008, 88:1413-1418.
12. Steck SE, Keku T, Butler LM, Galanko J, Massa B, Millikan RC, Sandler RS. Polymorphisms in methionine synthase, methionine synthase reductase and serine hydroxymethyltransferase, folate and alcohol intake, and colon cancer risk. J Nutrigenet Nutrigenomics 2008, 1:196-204. 10.1159/000136651, 2758622, 19776626.
13. Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, Moriya Y, van de Velde CJ, van Krieken JH. Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 2001, 195:171-178. 10.1002/path.918, 11592095.
14. Howard RA, Freedman DM, Park Y, Hollenbeck A, Schatzkin A, Leitzmann MF. Physical activity, sedentary behavior, and the risk of colon and rectal cancer in the NIH-AARP Diet and Health Study. Cancer Causes Controls 2008, 19:939-953.
15. Frattini M, Balestra D, Suardi S, Oggionni M, Alberici P, Radice P, Costa A, Daidone MG, Leo E, Pilotti S, Bertario L, Pierotti MA. Different genetic features associated with colon and rectal carcinogenesis. Clin Cancer Res 2004, 10:4015-4021. 10.1158/1078-0432.CCR-04-0031, 15217933.
16. Adams KF, Leitzmann MF, Albanes D, Kipnis V, Mouw T, Hollenbeck A, Schatzkin A. Body mass and colorectal cancer risk in the NIH-AARP Cohort. Am J Epidemiol 2007, 166:36-45. 10.1093/aje/kwm049, 17449892.
17. Le Marchand L, Wilkens LR, Kolonel LN, Henderson BE. The MTHFR C677T polymorphism and colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2005, 14:1198-1203. 10.1158/1055-9965.EPI-04-0840, 15894672.
18. Kim DH, Ahn YO, Lee BH, Tsuji E, Kiyohara C, Kono S. Methylenetetrahydrofolate reductase polymorphism, alcohol intake, and risks of colon and rectal cancers in Korea. Cancer Lett 2004, 216:199-205. 10.1016/j.canlet.2004.08.014, 15533596.
19. Cao HX, Gao CM, Takezaki T, Wu JZ, Ding JH, Liu YT, Li SP, Su P, Cao J, Hamajima N, Tajima K. Genetic polymorphisms of methylenetetrahydrofolate reductase and susceptibility to colorectal cancer. Asian Pac J Cancer Prev 2008, 9:203-208.
20. Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. EARS group. Atherosclerosis 1998, 136:347-354. 10.1016/S0021-9150(97)00237-2, 9543106.
21. Pereira AC, Schettert IT, Morandini AAF, Guerra-Shinohara EM, Krieger JE. Methylenetetrahydrofolate reductase (MTHFR) c677t gene variant modulates the homocysteine folate correlation in a mild folate deficient population. Clin Chim Acta 2004, 340:99-105. 10.1016/j.cccn.2003.09.016, 14734201.
22. Bailey LB, Duhaney RL, Maneval DR, Kauwell GP, Quinlivan EP, Davis SR, Cuadras A, Hutson AD, Gregory JF. Vitamin B-12 status is inversely associated with plasma homocysteine in young women with C677T and/or A1298C methylenetetrahydrofolate reductase polymorphisms. J Nutr 2002, 132:1872-1878.
23. Sassi S, Cosmi B, Palareti G, Legnani C, Grossi G, Musolesi S, Coccheri S. Influence of age, sex and vitamin status on fasting and post-methionine load plasma homocysteine levels. Haematologica 2002, 87:957-964.
24. Marchesini G, Manini R, Bianchi G, Sassi S, Natale S, Chierici S, Visani F, Baraldi L, Forlani G, Melchionda N. Homocysteine and psychological traits: a study in obesity. Nutrition 2002, 18:403-407. 10.1016/S0899-9007(01)00803-6, 11985945.
25. Parsons DS, Reaveley DA, Pavitt DV, Brown EA. Relationship of renal function to homocystein and lipoprotein(a) levels: The frequency of the combination of both risk factors in chronic renal impairment. Am J Kidney Dis 2002, 40:916-923. 10.1053/ajkd.2002.36321, 12407635.
26. Valik D, Radina M, Sterba J, Vojtesek B. Homocysteine: exploring its potential as a pharmacodynamic biomarker of antifolate chemotherapy. Pharmacogenomics 2004, 5:1151-1162. 10.1517/14622416.5.8.1151, 15584881.
27. Wu LL, Wu JT. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin Chim Acta 2002, 322:21-28. 10.1016/S0009-8981(02)00174-2, 12104077.
28. Oikawa S, Murakami K, Kawanishi S. Oxidative damage to cellular and isolated DNA by homocysteine: implications for carcinogenesis. Oncogene 2003, 22:3530-3538. 10.1038/sj.onc.1206440, 12789261.
29. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuve LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995, 10:111-113. 10.1038/ng0595-111, 7647779.
30. Lee WC, Wang LY. Simple formulas for gauging the potential impacts of population stratification bias. Am J Epidemiol 2007, 167:86-89. 10.1093/aje/kwm257, 17881384.
31. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. dbSNP accession: {rs1979277 and rs1801133}, (dbSNP Build ID: 129) , http://www.ncbi.nlm.nih.gov/SNP/
32. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidences, mortality and prevalence worldwide. IARC Cancer Base No. 5 version 2.0. 2004, Lyon, France: IARC Press.
33. Wang Y, Guo W, He Y, Chen Z, Wen D, Zhang X, Wang N, Li Y, Ge H, Zhang J. Association of MTHFR C677T and SHMT(1) C1420T with susceptibility to ESCC and GCA in a high incident region of Northern China. Cancer Causes Control 2007, 18:143-152. 10.1007/s10552-006-0097-4, 17206530.
34. Taioli E, Garza MA, Ahn YO, Bishop DT, Bost J, Budai B, Chen K, Gemignani F, Keku T, Lima CSP, Le Marchand L, Matsuo K, Moreno V, Plaschke J, Pufulete M, Thomas SB, Toffoli G, Wolf CR, Moore CG, Little J. Meta- and pooled analyses of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review. Am J Epidemiol 2009, 170:1207-1221. 10.1093/aje/kwp275, 19846566.
35. Huang Y, Han S, Li Y, Mao Y, Xie Y. Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis. J Hum Genet 2007, 52:73-85. 10.1007/s10038-006-0082-5, 17089070.
36. Zajkás G, Bíró L, Greiner E, Szórád I, Ágoston H, Balázs A, Vitrai J, Hermann D, Boros J, Németh R, Kéki Z, Martos T. Dietary survey in Hungary, 2003-2004. Micronutrients: vitamins. Orv Hetil 2007, 148:1593-1600. 10.1556/OH.2007.28182, 17702688.
37. Iacopetta B, Heyworth J, Girschik J, Grieu F, Clayforth C, Fritschi L. The MTHFR C677T and ΔDNMT3B C-149T polymorphism confer different risks for right- and left-sided colorectal cancer. Int J Cancer 2009, 125:84-90. 10.1002/ijc.24324, 19326430.
38. Liang W. Age sex and the risk of grade-specific second primary colorectal cancer: Evidence for the protective effect of female hormone. Eur J Cancer 2007, 43:1856-1861. 10.1016/j.ejca.2007.05.015, 17604155.
39. Mrkonjic M, Raptis S, Green RC, Monga N, Daftary D, Dicks E, Younghusband HB, Parfrey PS, Gallinger SS, McLaughlin JR, Knight JA, Bapat B. MSH2 118T > C and MSH6 159C > T promoter polymorphisms and the risk of colorectal cancer. Carcinogenesis 2007, 28:2575-2580. 10.1093/carcin/bgm229, 17942459.
40. Talseth BA, Ashton KA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. Aurora-A and Cyclin D1 polymorphisms and the age of onset of colorectal cancer in hereditery nonpoliposis colorectal cancer. Int J Cancer 2007, 122:1273-1277.
41. Slattery ML, Sweeney C, Murtaugh M, Ma KN, Potter JD, Levin TR, Samowitz W, Wolff R. Associations between apoE genotype and colon and rectal cancer. Carcinogenesis 2005, 26:1422-1429. 10.1093/carcin/bgi088, 15817610.
42. Jacobs ET, Ahnen DJ, Ashbeck EL, Baron JA, Greenberg ER, Lance P, Lieberman DA, McKeown-Eyssen G, Schatzkin A, Thompson PA, Martínez ME. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. Am J Epidemiol 2009, 169:657-666. 10.1093/aje/kwn401, 2727215, 19147743.
43. Geisel J, Hübner U, Bodis M, Schorr H, Knapp JP, Obeid R, Herrmann W. The role of genetic factors in the development of hyperhomocysteinemia. Clin Chem Lab Med 2003, 41:1427-1434. 10.1515/CCLM.2003.219, 14656021.
44. Semmler A, Moskau S, Stoffel-Wagner B, Weller M, Linnebank M. The effect of MTHFR c.677C > T on plasma homocysteine levels depends on health, age and smoking. Clin Invest Med 2009, 32:E310-E314.
45. Schroecksnadel K, Frick B, Fiegl M, Winkler C, Denz HA, Fuchs D. Hyperhomocysteinaemia and immune activation in patients with cancer. Clin Chem Lab Med 2007, 45:47-53. 10.1515/CCLM.2007.012, 17243914.
46. Ferroni P, Palmirotta R, Martini F, Riondino S, Savonarola A, Spila A, Ciatti F, Sini V, Mariotti S, Del Monte G, Roselli M, Guadagni F. Determinants of homocysteine levels in colorectal and breast cancer patients. Anticancer Res 2009, 29:4131-4138.
47. Almadori G, Bussu F, Galli J, Cadoni G, Zappacosta B, Persichilli S, Minucci A, Giardina B. Serum folate and homocysteine levels in head and neck squamous cell carcinoma. Cancer 2002, 94:1006-1011. 10.1002/cncr.10343, 11920469.
48. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991, 51:828-835.
49. Ozkan Y, Yardim-Akaydin S, Firat H, Calişkan-Can E, Ardiç S, Simşek B. Usefulness of homocysteine as a cancer marker: total thiol compounds and folate levels in untreated lung cancer patients. Anticancer Res 2007, 27:1185-1189.
50. Battistelli S, Vittoria A, Stefanoni M, Bing C, Roviello F. Total plasma homocysteine and methylenetetrahydrofolate reductase C677T polymorphism in patients with colorectal carcinoma. World J Gastroenterol 2006, 12:6128-6132.
51. Eleftheriadou A, Chalastras T, Ferekidou E, Yiotakis I, Kyriou L, Tzagarakis M, Ferekidis E, Kandiloros D. Association between squamous cell carcinoma of the head and neck and serum folate and homocysteine. Anticancer Res 2006, 26:2345-2348.
52. Zacho J, Yazdanyar S, Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG. Hyperhomocysteinemia, methylenetetrahydrofolate reductase c.677C > T polymorphism, and risk of cancer: cross-sectional and prospective studies and meta-analyses of 75,000 cases and 93,000 controls. Int J Cancer 2010,
53. Gatt A, Makris A, Cladd H, Burcombe RJ, Smith JM, Cooper P, Thompson D, Makris M. Hyperhomocysteinemia in women with advanced breast cancer. Int J Lab Hematol 2007, 29:421-425. 10.1111/j.1751-553X.2007.00907.x, 17988296.
54. Ruud E, Holmstrøm H, Brosstad F, Wesenberg F. Diagnostic value of family histories of thrombosis to identify children with thrombophilia. Pediatr Hematol Oncol 2005, 22:453-462. 10.1080/08880010591002224, 16169812.
55. Melichar B, Kalábová H, Krcmová L, Kasparová M, Malírová E, Melicharová K, Pecka M, Hyspler R, Solichová D. Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin. Anticancer Res 2009, 29:4813-4820.
56. Anderson DD, Stover PJ. SHMT1 and SHMT2 are functionally redundant in nuclear de novo thymidylate biosynthesis. PLoS ONE 2009, 4:e5839. 10.1371/journal.pone.0005839, 2688753, 19513116.